Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Deggingen – page 35

1 295 clinical trials in Deggingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Deggingen at a glance
1 295
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 295 trials in Deggingen

Open in trial search

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effects of Prasinezumab in Patients with Early Parkinson's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:F. Hoffmann-La Roche AG

Oxygen Therapy for Pregnant Women to Support Heart Development in Unborn Babies with Underdeveloped Left Heart Structures

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Oxygen
  • Sponsor:Universitaetsklinikum Erlangen AöR

Study on the Effectiveness and Safety of NS-229 for Patients with Eosinophilic Granulomatosis with Polyangiitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Methyl-(1-{[6-{[(1S)-1-Cyclopropylethyl]Amino}-2-(Pyrazolo[5,1-B][1,3]Thiazol-7-Yl)-Pyrimidin-4-Yl]Carbonyl}Piperidin-4-Yl)Carbamate-Mono(4-Methylbenzenesulfonate) Monohydrate
  • Sponsor:Ns Pharma Inc.

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Neoplasm malignant+7

Recruiting

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Exelixis Inc.

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Study on Mesenchymal Stromal Cells (MC0518) for Treating Steroid-Resistant Acute Graft Versus Host Disease in Adults and Adolescents

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Medac Gesellschaft fuer klinische Spezialpraeparate mbH

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Institut Gustave Roussy

Study on the Safety and Tolerability of STK-002 for Patients with Autosomal Dominant Optic Atrophy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:STK-002
  • Sponsor:Stoke Therapeutics Inc.

Study on the Safety and Effectiveness of Baricitinib for Children Aged 1 to 17 with Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Glioblastoma

Recruiting

Study on Glioblastoma Treatment with Olaptesed Pegol and Radiation, with Bevacizumab or Pembrolizumab, for Patients with Unmethylated MGMT Promoter

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:TME Pharma AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Deggingen

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on heart failure prevention and managing atrial fibrillation, exploring new therapeutic approaches for cardiac conditions.

  • Heart Failure Prevention Studies
  • Cardioembolic Event Prevention
  • Blood Pressure Management

Research includes evaluation of novel drug combinations and preventive therapies for cardiovascular outcomes.

02 Metabolic Disorders

Comprehensive research on hypertriglyceridemia and Type 2 Diabetes Mellitus, testing new treatments for metabolic conditions.

  • Triglyceride Level Management
  • Diabetes Cardiovascular Outcomes
  • Metabolic Disease Therapies

Studies aim to improve treatment options and long-term patient outcomes in metabolic disorders.

03 Respiratory Medicine

Advanced research targeting Chronic Obstructive Pulmonary Disease, investigating new therapeutic approaches for respiratory conditions.

  • COPD Exacerbation Management
  • Respiratory Disease Treatment
  • Long-term Disease Control

Focus on reducing acute exacerbations and improving quality of life for COPD patients.

04 Other Therapeutic Areas

Studies addressing gout with hyperuricemia and various forms of hypertension, developing targeted treatments.

  • Uric Acid Management
  • Resistant Hypertension Studies
  • Long-term Safety Evaluations

Research aimed at developing effective treatments for complex medical conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.